Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Efficacy and Safety of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP)

NCT07294365 is registered in ClinicalTrials.gov with Dizal Pharmaceuticals as lead sponsor.

NCT NCT07294365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07294365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Efficacy and Safety of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP)
Lead sponsor
Dizal Pharmaceuticals
Phase
Phase 2
Overall status
Recruiting
Start date
January 15, 2026
Completion date
December 31, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia (itp)